COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW. Kartika Jurnal Ilmiah Farmasi, v. 9, n. 1, p. 37–53, 29 Apr.2024.